Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$194.29 USD

194.29
4,749,724

-1.16 (-0.59%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $193.90 -0.39 (-0.20%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

AbbVie (ABBV) is a Top Dividend Stock Right Now: Should You Buy?

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.

AbbVie (ABBV) Announces Appointment of New CEO Robert Michael

Robert Michael is set to succeed Richard A. Gonzalez as AbbVie's (ABBV) CEO, effective Jul 1, 2024.

Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?

Smart Beta ETF report for PJP

Is ProShares S&P 500 Dividend Aristocrats ETF (NOBL) a Strong ETF Right Now?

Smart Beta ETF report for NOBL

3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income

The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It

Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.

Ironwood (IRWD) Q4 Earnings Miss, Revenues Beat Marginally

Ironwood's (IRWD) fourth-quarter 2023 earnings lag estimates while revenues beat the same marginally. Linzess collaboration revenues drive the top line.

The Zacks Analyst Blog Highlights AbbVie, Applied Materials, American Express, Centene and Aspen

AbbVie, Applied Materials, American Express, Centene and Aspen are included in this Analyst Blog.

Sheraz Mian headshot

Top Stock Reports for AbbVie, Applied Materials & American Express

Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), Applied Materials, Inc. (AMAT) and American Express Company (AXP).

3 Top Dividend Stocks to Maximize Your Retirement Income

The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

Novartis (NVS) to Buy MorphoSys & Add Late-Stage Oncology Drug

Novartis (NVS) announces an agreement to acquire Germany-based MorphoSys AG and add the latter's late-stage candidate pelabresib to its pipeline.

AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know

AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Is WisdomTree U.S. High Dividend ETF (DHS) a Strong ETF Right Now?

Smart Beta ETF report for DHS

This is Why AbbVie (ABBV) is a Great Dividend Stock

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.

How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks

The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, AbbVie and Novartis

Eli Lilly, Novo Nordisk, AbbVie and Novartis have been highlighted in this Industry Outlook article.

AbbVie (ABBV) Q4 Earnings Beat, Raises Sales View for Key Drugs

AbbVie???s (ABBV) fourth-quarter earnings and sales beat estimates. Management hikes the 2027 forecast for new immunology drugs to more than $27 billion.

Nonfarm Payrolls Increased More Than Expected

Nonfarm Payrolls Increased More Than Expected

Mark Vickery headshot

BLS Jobs Up Big: 353K, 3.7% Unemployment

353K new jobs created for January are nearly double the 180K or so analysts were looking for.

AbbVie (ABBV) Reports Q4 Earnings: What Key Metrics Have to Say

The headline numbers for AbbVie (ABBV) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Kinjel Shah headshot

4 Large Drug Stocks Trying to Survive the Industry Challenges

Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), AbbVie (ABBV) and Novartis (NVS) are worth retaining in one's portfolio.

AbbVie (ABBV) Q4 Earnings and Revenues Top Estimates

AbbVie (ABBV) delivered earnings and revenue surprises of 1.09% and 1.78%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Merck (MRK) Beats Q4 Earnings Estimates

Merck (MRK) delivered earnings and revenue surprises of 133.33% and 0.45%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

AbbVie (ABBV) to Report Q4 Earnings: What's in the Cards?

AbbVie's (ABBV) Q4 performance will likely reflect its newer immunotherapy drugs trying to compensate for declining Humira sales following the loss of U.S. exclusivity.

Eli Lilly (LLY) Earnings Expected to Grow: Should You Buy?

Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.